Every paper, in order.

Citation list

The full numbered reference list is rendered below the heading by the assembler from references_index. Each entry links to the primary source — PubMed, PMC, the FDA accessdata archive, or the journal article landing page. All DOIs and PMIDs match the records in our research corpus.

How this list was built

Every citation on this site is anchored in a peer-reviewed source, a primary regulatory document (FDA new drug application archive), a WADA Prohibited List entry, or a USP-promulgated compounding-pharmacy chapter. We do not cite secondary commentary, supplement-industry marketing, social-media posts, or aggregator articles. Where a claim could be sourced to either an original trial or a later review, we cite both — the trial for the data point, the review for the interpretive context. Where the literature is sparse (long-term safety, head-to-head comparisons of native sermorelin against modern GHRH analogs), we say so on the page rather than dressing thin evidence as strong evidence.

The inline [N] markers across this site reference the numbered list below. Numbering is stable across pages — citation ^[3] on the research page is the same Khorram 1997 trial that ^[3] points to on the FAQ. The list is sorted by first appearance on the index page, then by first appearance on subsequent pages in section order.